Biomarkers in Prostate Cancer: Are We Identifying Lethal Disease?

Michael S. Leapman, MD, MHS, associate professor of urology at Yale University, addresses a critical and often overlooked limitation in the current landscape of prostate cancer biomarkers: while these tools have advanced the field by reducing false positives associated with PSA screening, they still fall short of answering the most clinically meaningful question: Does a patient have a potentially lethal prostate cancer?

Dr Leapman acknowledges that biomarkers available today for pre-biopsy risk stratification represent a meaningful step forward. All of them are designed around a standardized definition of clinically significant prostate cancer, typically defined as Gleason grade group 2 or higher. This threshold reflects disease that clinicians generally agree warrants attention and monitoring. However, Dr Leapman cautions that this end point, while useful, does not fully align with the ultimate goal of prostate cancer management: identifying patients whose disease is genuinely life-threatening and who would derive a mortality benefit from early intervention.

The distinction he draws is subtle but consequential. Detecting high-grade disease in the prostate is not the same as detecting lethal disease. By focusing on the former, current biomarkers may be inadvertently driving overtreatment in a population of patients whose cancers would never have caused them harm. In other words, a positive biomarker result may prompt aggressive intervention in men whose prostate cancer was destined to remain indolent throughout their lifetime.

Dr Leapman suggests that the next frontier for biomarker development should be identifying patients at true mortality risk: those for whom treatment will meaningfully reduce the chance of dying from prostate cancer. Reaching that goal, he implies, would represent a transformative shift in how the field approaches early detection and treatment decision-making.